Pyxis Oncology, Inc.

NASDAQ:PYXS

Biotechnology

Healthcare
$1.41 +5.53%

+$0.11 today

Market cap
$168.65M
Beta
1.43
P/E (TTM)
-1.6
EPS (TTM)
-$1.29
52W Low $0.97High $5.55

Volume 0.75M

Average 0.50M

PYXS Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Pyxis Oncology, Inc.NASDAQ: PYXS

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables grows, but more slowly than its trailing trend

Q1 FY2026 accounts payables of $5.9M (cash outflow) rose 192.9% year over year, behind the +288.2% change in trailing-twelve-month accounts payables.

Context

  • Accounts payables amounted to 43.5% of revenue in FY2025, up 36.1 pp from a year earlier.
  • Accounts payables increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +192.9% toward the trailing-twelve-month pace of +288.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$5.9M-622.2% QoQ
Last fiscal yearDec 2025
$6.03M+402.2% YoY
LTMMar 2026
$2.14M+288.2% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+192.9%——
1 year+402.2%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
6.03M USD
Year-over-year change
+402.2%
4-year CAGR
+6.7%

Accounts Payables vs competitors

How PYXS compares with its peers on the latest reported figures

  • PYXS's LTM Mar 2026 accounts payables of $2.14M is the 3rd largest of the 10 companies compared; the peer median is $42K.
  • Its year-over-year change of +288.2% is the 2nd highest of 10, against a peer median of +12.5%.
  • Accounts payables amounts to 15.5% of revenue for PYXS, versus a peer median of 2.4%.
PYXS Competitors Peer median
Accounts Payables for PYXS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ZURAZura Bio LimitedLTM Mar 2026$4.96M -177.6%——
TNYATenaya Therapeutics, Inc.LTM Mar 2026$2.51M +12.5%—1116.0%
PYXSPyxis Oncology, Inc.LTM Mar 2026$2.14M +288.2%—15.5%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$2.06M +115.0%——
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$793K -49.2%-33.2%2.8%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$399K +1230.0%-34.4%0.6%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$370K -77.8%—3.3%
IMRXImmuneering CorporationLTM Mar 2026$197.49K +121.5%——
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$89K +101.8%-20.1%0.2%
HUMAHumacyte, Inc.LTM Mar 2026$42K -102.6%—2.1%
Peer median (excluding PYXS) $42K+12.5%-33.2%2.4%

Competitors are the stored peer set for PYXS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(75.98M)(120.72M)(73.79M)(77.33M)(79.62M)
Depreciation & Amortization647K709K1.93M2.98M4.51M
Deferred Income Tax6.28M0000
Stock-Based Compensation6.44M15.76M16.95M12.95M11.8M
Change in Working Capital6.68M4.5M(11.66M)(11.82M)1.94M
Accounts Receivables00000
Inventory00000
Accounts Payables4.64M(8.33M)(3.51M)1.2M6.03M
Other Working Capital2.03M12.83M(8.16M)(13.02M)(4.08M)
Other Non-Cash Items20.6M10.41M(4.13M)15.56M(2.14M)
Operating Cash Flow(35.33M)(89.34M)(70.71M)(57.67M)(63.5M)
Capital Expenditures(540K)(6.4M)(6.73M)(237K)(9K)
Acquisitions (Net)(50K)06.66M00
Purchases of Investments(50K)0(196.83M)(160.12M)(107.01M)
Sales of Investments50.05K092.05M168.51M165.87M
Other Investing Activities(50)0000
Investing Cash Flow(590K)(6.4M)(104.85M)8.16M58.86M
Debt Repayment00000
Common Stock Issued152.3M06.12M59.05M742K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities167K183K(193K)280K(148K)
Financing Cash Flow304.04M183K5.93M59.33M594K
Effect of Forex Changes00000
Net Change in Cash268.13M(95.55M)(169.63M)9.81M(4.05M)
Free Cash Flow(35.87M)(95.73M)(77.44M)(57.91M)(63.51M)

Pyxis Oncology, Inc.

NASDAQ:PYXS

Intrinsic Alpha fair value

Locked

Current Price

$1.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.